An Indiana CDMO with big-name clients sets up plans for lentiviral production site
An Indiana CDMO focused on gene therapy is cashing in on the industry’s hot streak and unveiling a master plan for a 75,000-square-foot lentiviral vector production site.
Genezen Laboratories broke ground on the construction of a new plant outside Indianapolis, IN. It will complete the first phase of construction — good for 25,000 square feet — by autumn 2021, and the rest of the facility will go online by early 2022, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.